VEGFA and cancer: In particular, four classes of cancer drugs were attributed to induce the cardiac complications in oncologic patients: anthracyclines, vascular endothelial growth factor (VEGF)-, human epidermal growth factor receptor 2 (HER2)-, and tyrosine kinase (TK)-targeted inhibitors (including monoclonal antibodies).